Harbin Sanlian has released its earnings forecast, expecting a net loss attributable to the parent company of 38 million to 48 million yuan for the first half of 2026, compared with a loss of 92.3904 million yuan in the same period last year. The company also expects to achieve operating revenue of 429 million yuan, a net loss excluding non-recurring items of 47 million to 57 million yuan, and a basic loss per share of 0.12 to 0.15 yuan. The announcement stated that due to the impact of the national centralized drug procurement policy and intense competition in some non-procurement formulation markets, product prices are sluggish, while fixed costs are relatively rigid, making it difficult for gross profit to cover period expenses, which is the direct cause of the negative net profit. In addition, the fair value of the company's investment in the Hong Kong-listed SSY Group continued to decline, with a fair value change loss of 9.7902 million yuan during the reporting period.
SSY Group LtdFair value of Harbin Sanlian's investment in SSY Group declined, causing a loss of 9.79 million yuan.
Harbin Medisan Pharmaceutical Co LtdNational centralized drug procurement policy and intense competition in non-procurement markets caused product price sluggishness and net loss.